Scientific Research Publishing3d
The Cause of Hirschsprung’s Disease in Bardet Biedl Syndrome in Children ()
Both HSCR and BBS can significantly impact a child’s quality of life. HSCR can lead to complications such as intestinal ...
Business Insider17d
Non-Profit Organization A Race Against Blindness Donates $1 Million to Bardet-Biedl Syndrome Research
Clinical Research to Address Bardet-Biedl Syndrome Bardet-Biedl Syndrome ... inspired by their personal experience with their son's diagnosis of a vision-loss condition. A Race Against Blindness ...
MedPage Today26d
Imcivree Label Expanded; Weight Loss With Weekly Injection; Kidney Donation Chain
Opens in a new tab or window The FDA expanded the indication for setmelanotide (Imcivree) to include children as young as 2 years with syndromic or monogenic obesity due to Bardet-Biedl syndrome ...
Healio26d
FDA expands setmelanotide approval for rare forms of obesity to children aged 2 to 5 years
Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is a melanocortin-4 receptor agonist that the FDA previously approved for chronic weight management in people with Bardet-Biedl syndrome in 2022 ...
Endocrinology Advisor13d
Imcivree Approved for Younger Patients With Obesity Due to MC4R Deficiency
Results from the VENTURE trial showed significant reductions in weight and hunger among younger patients treated with setmelanotide.
Yahoo Finance1mon
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome ...
Monthly Prescribing Reference1mon
Imcivree Approved for Younger Patients With Obesity Due to MC4R Deficiency
The Food and Drug Administration (FDA) has expanded the approval of Imcivree ® (setmelanotide) to include children as young as 2 years old with obesity due to Bardet-Biedl syndrome (BBS ...